Guest Editors
Prof. Dr. Nicola Pavan
Email: nicpavan@gmail.com
Affiliation: Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90133, Italy.
Homepage:
Research Interests: uro-oncology; minimally invasive surgery, immunotherapy, and multimodal treatments in genitourinary malignancies
Dr. Francesco Claps
Email: claps.francesco@gmail.com
Affiliation: Oncological Urology, Department of Surgical Oncology, Veneto Institute of Oncology, Padua, 35128, Italy.
Homepage:
Research Interests: genitourinary cancers; minimally-invasive oncological surgery
Summary
The landscape of genitourinary (GU) oncology is rapidly evolving, driven by breakthroughs in immunotherapy and its integration with other treatment modalities. Immunotherapeutic approaches, such as immune checkpoint inhibitors, have significantly improved outcomes in bladder, kidney, and prostate cancers, yet their full potential is realized when combined with surgery, radiotherapy, and systemic therapies. Understanding how to optimize these multimodal strategies is a critical challenge in current oncological practice.
This Special Issue aims to provide a comprehensive overview of the latest advances in immunotherapy and its synergistic role within multimodal treatment frameworks for GU malignancies. The objective is to highlight both translational and clinical research that can inform innovative therapeutic combinations and patient selection strategies, with the ultimate goal of enhancing survival and quality of life.
We invite original research articles, reviews, and clinical perspectives addressing:
· Novel immunotherapeutic agents and combination regimens
· Mechanisms of resistance and strategies to overcome them
· Biomarkers for patient stratification and treatment response
· Integration of surgery, radiation, and systemic therapies with immunotherapy
· Real-world data and clinical trial updates in localized and metastatic GU cancers
This Special Issue will serve as a platform for advancing knowledge and fostering collaboration among clinicians and researchers in the field of GU oncology.
Keywords
genitourinary cancers, immunotherapy, multimodal treatment, immune checkpoint inhibitors, combination therapy, biomarkers, resistance mechanisms, translational oncology
Login
Register
Submit a Paper
Propose a Special lssue